Presentation is loading. Please wait.

Presentation is loading. Please wait.

Myeloablative Autologous Transplantation of CD34 + Selected Hematopoietic Stem Cells (HSCT) vs Monthly Intravenous Cyclophosphamide (CY) for Severe Scleroderma.

Published byΜελπομένη Βλαχόπουλος Modified over 5 years ago

Similar presentations

Presentation on theme: "Myeloablative Autologous Transplantation of CD34 + Selected Hematopoietic Stem Cells (HSCT) vs Monthly Intravenous Cyclophosphamide (CY) for Severe Scleroderma."— Presentation transcript:

1 Myeloablative Autologous Transplantation of CD34 + Selected Hematopoietic Stem Cells (HSCT) vs Monthly Intravenous Cyclophosphamide (CY) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial  Keith Sullivan, Lynettee Keyes-Elstein, Peter McSweeney, Ashley Pinckney, Beverly Welch, Maureen Mayes, Richard Nash, Leslie Crofford, Sharon Castina, Linda M. Griffith, Ellen Goldmuntz, Daniel Furst  Biology of Blood and Marrow Transplantation  Volume 23, Issue 3, Pages S23-S24 (March 2017) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Global rank composite score.
Biology of Blood and Marrow Transplantation  , S23-S24DOI: ( /j.bbmt ) Copyright © Terms and Conditions

3 Figure 2 Kaplan-Meier estimates.
Biology of Blood and Marrow Transplantation  , S23-S24DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Myeloablative Autologous Transplantation of CD34 + Selected Hematopoietic Stem Cells (HSCT) vs Monthly Intravenous Cyclophosphamide (CY) for Severe Scleroderma."

Similar presentations

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.
Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome  Joseph Delano F. Robles, Daniel.

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome  Joseph Delano F. Robles, Daniel.
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.
Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation.

Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era  Sarah F. Keller,

Late Relapses following High-Dose Autologous Stem Cell Transplantation (HD-ASCT) for Hodgkin’s Lymphoma (HL) in the ABVD Therapeutic Era  Sarah F. Keller,
Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.

Outcomes of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Progressing after Autologous Hematopoietic Stem Cell Transplant  Maria Gil-Cupello, BA, Gunjan.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G- CSF and Plerixafor Compared to G-CSF and Cyclophosphamide  Paul Shaughnessy,

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G- CSF and Plerixafor Compared to G-CSF and Cyclophosphamide  Paul Shaughnessy,
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.

Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.
Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,

Optimizing Data Collection for Long-Term Follow-Up after Hematopoietic Stem Cell Transplant  Jaskiran Kaur, Madhu Ragupathi, Alysa Pleiner, Luda Kushner,
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients 60-75 Years of Age with Secondary Acute.

Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.
Gregory Wallace, DO, Sonata Jodele, MD, Kasiani C

Gregory Wallace, DO, Sonata Jodele, MD, Kasiani C
A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

Similar presentations

Ads by Google